- Pharma
- 1 min read
Siddharth Mittal takes over as CEO and Joint MD of Biocon
Mittal has been serving as Chief Financial Officer (CFO) since August 2014. He has replaced Dr. Arun Chandavarkar who retired as Chief Executive Officer & Joint MD of Biocon on November 30.
Mittal has been serving as Chief Financial Officer (CFO) since August 2014. He has replaced Dr. Arun Chandavarkar who retired as Chief Executive Officer & Joint MD of Biocon on November 30.
Mittal has played a pivotal role in managing global collaborations. As the CFO, he has successfully created a compelling Shareholder Value Proposition for Biocon over the last 6 years, including value unlocking of Syngene which was listed on the Indian capital markets in 2015, the pharma major said in a statement.
“Siddharth’s strong leadership qualities, comprehensive understanding of various aspects of the business, deep financial insights and robust operational experience make him an excellent fit for the role of CEO to lead Biocon through its next phase of growth.” said Kiran Mazumdar-Shaw, CMD, Biocon.
Siddharth brings with him over 20 years of experience in the fields of general management, strategic finance and accounting, mergers and acquisitions, taxation etc.
“Post the creation of Biocon Biologics as a wholly owned subsidiary, I now look forward to generating value for our stakeholders by focusing on our Small Molecules business with an aim to further strengthen our portfolio of complex APIs and Generic Formulations in key global markets, “ said Siddharth Mittal, CEO & Joint Managing Director, Biocon.
COMMENTS
All Comments
By commenting, you agree to the Prohibited Content Policy
PostBy commenting, you agree to the Prohibited Content Policy
PostFind this Comment Offensive?
Choose your reason below and click on the submit button. This will alert our moderators to take actions